secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2023-02-10T23:59:59+00:00
Accession:  0001493152-23-004202
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo reports Q2 fiscal 2023 net loss of $3.8M; Phase 2 trial completed for ANEB-001
--------------------------------------------------------------------------------

- Net loss of $3.8M ($0.15 per share) vs $1.1M ($0.05) in Q2 fiscal 2022.
- Cash and cash equivalents of $16.4M as of Dec 31, 2022.
- Completed dosing Phase 2 trial for ANEB-001; preliminary data shows 10mg dose reduces key ACI symptoms.
- Final Phase 2 data expected by end Q1 2023; End-of-Phase 2A meeting with FDA expected Q2 2023.
- Continued development of parenteral formulation of ANEB-001.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315223004202/0001493152-23-004202-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315223004202/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-004202

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer